|Videos|October 6, 2022
Risk Stratification for Patients with Myelodysplastic Syndrome
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.
Advertisement
Episodes in this series
Advertisement
Related to this article
The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or refractory acute leukemia.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA granted orphan drug designation to Cardiff Oncology’s PLK1 inhibitor onvansertib for relapsed or refractory CMML after early phase 1 activity.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5